HC Wainwright & Co. Maintains Buy on Fate Therapeutics, Raises Price Target to $7

Benzinga Newsdesk www.benzinga.com Positive 55.2%

Neg 0% Neu 0% Pos 55.2%

HC Wainwright & Co. analyst Robert Burns maintains Fate Therapeutics (NASDAQ:FATE) with a Buy and raises the price target from $5 to $7.